Cigna earnings beat by $0.04, revenue topped estimates
Investing.com -- SigmaRoc reported first-half revenues and EBITDA in line with expectations, with revenue up 13% and EBITDA increasing 22% compared to the same period last year, primarily driven by acquisitions.
The company saw a 1% decline in like-for-like sales, but comparable EBITDA margins improved by 70 basis points to 23.1%, which the company attributed to synergy benefits and an improved product mix.
SigmaRoc shares rose 1.5% following the announcement.
Despite challenging market conditions, management expressed confidence in meeting full-year market expectations. The company now expects to exceed its 2025 synergy target of over £17 million, while maintaining its long-term target of €40-60 million in total synergies.
The results represent a strong performance for SigmaRoc as its end markets continue to remain soft.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.